Trials / Sponsors / Anchiano Therapeutics Israel Ltd.
Anchiano Therapeutics Israel Ltd.
Industry · 6 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | 2019-03-20 |
| Completed | Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma Transitional Cell Carcinoma of Bladder | Phase 1 | 2013-02-01 |
| Terminated | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma Pancreas, Adenocarcinoma | Phase 2 | 2011-09-01 |
| Completed | Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer Pancreatic Neoplasms | Phase 1 / Phase 2 | 2009-08-01 |
| Completed | Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer Ovarian Cancer | Phase 1 / Phase 2 | 2009-06-01 |
| Completed | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer Superficial Bladder Cancer | Phase 2 | 2008-01-01 |